All In Biotech

Drug Trial Radar · NCT06345703

First-into-human Study of NS-136 in Healthy Subjects

A Phase 1, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and PK of Single and Multiple Ascending Oral Doses and Food Effect of NS-136 in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Nov 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

76

Planned (sponsor's estimate)

Start

Apr 30, 2024

Primary completion

Nov 2024

Study completion Feb 2025

Sponsor

Lead sponsor
NeuShen TherapeuticsIndustry
Sponsor type
Industry
First posted
Apr 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to exlplore the profile of NS-136 in health conditions. The main questions it aims to answer are: * Is NS-136 safe and tolerable in heathy subjects under tested dosing regimen? * What is the pharmacokinectic profile of NS-136 in healthy subjects under tested dosing regimen?

Conditions

  • Healthy Subjects

Interventions

  • PlaceboDrug

    NS-136 matching placebo

  • NS-136 tabletDrug

    Investigational product NS-136

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Treatment-Related Adverse EventsTime frame: for SAD, day 1-7; for MAD, day 1-26, for FE, day1-14
  2. Main pharmacokinetic parametersTime frame: for SAD, day 1-7; for MAD, day 1-26,
  3. Main pharmacokinetic parametersTime frame: for SAD, day 1-7; for MAD, day 1-26,
  4. Main pharmacokinetic parametersTime frame: for SAD, day 1-7; for MAD, day 1-26,
  5. Main pharmacokinetic parametersTime frame: for SAD, day 1-7; for MAD, day 1-26,
  6. Main pharmacokinetic parametersTime frame: for SAD, day 1-7; for MAD, day 1-26,
  7. Main pharmacokinetic parametersTime frame: for SAD, day 1-7; for MAD, day 1-26,

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • CMAX Clinical Research Pty Ltd

    Adelaide, South Australia, Australia · Recruiting

  • Chengdu Xinhua Hospital

    Chengdu, Sichuan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.